Experienced in Transient Erythroblastopenia of Childhood

Dr. Anurag K. Singh

Hematology Oncology | Hematology | Oncology
University Of Kansas Hospital Authority
3901 Rainbow Blvd, 
Kansas City, KS 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Experienced in Transient Erythroblastopenia of Childhood
University Of Kansas Hospital Authority
3901 Rainbow Blvd, 
Kansas City, KS 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Anurag Singh is a Hematologist Oncology specialist and a Hematologist in Kansas City, Kansas. Dr. Singh is rated as an Experienced provider by MediFind in the treatment of Transient Erythroblastopenia of Childhood. His top areas of expertise are Acute Myeloid Leukemia (AML), Head and Neck Squamous Cell Carcinoma (HNSCC), Acute Myeloblastic Leukemia without Maturation, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Singh is currently accepting new patients.

His clinical research consists of co-authoring 788 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Hospital Affiliations
University Of Kansas Hospital
Languages Spoken
English
Hindi
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Cox Health
  • EPO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Home State Health
  • EPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Sunflower Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

UNIVERSITY OF KANSAS HOSPITAL AUTHORITY
3901 Rainbow Blvd, Kansas City, KS 66160
Other Locations
UNIVERSITY OF KANSAS HOSPITAL AUTHORITY
2650 Shawnee Mission Pkwy, Westwood, KS 66205

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Enrollment Status: Recruiting
Publish Date: October 14, 2025
Intervention Type: Procedure, Drug, Other, Radiation, Biological
Study Drugs: Atezolizumab, Cetuximab, Cisplatin, Docetaxel
Study Phase: Phase 2/Phase 3
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
Enrollment Status: Suspended
Publish Date: October 10, 2025
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 3
Intensive Symptom Surveillance Guided by Machine Learning-Directed Risk Stratification (INSIGHT)
Intensive Symptom Surveillance Guided by Machine Learning-Directed Risk Stratification (INSIGHT)
Enrollment Status: Active_not_recruiting
Publish Date: October 02, 2025
Intervention Type: Other
Study Phase: Not Applicable
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Enrollment Status: Completed
Publish Date: September 23, 2025
Intervention Type: Other, Biological, Radiation
Study Drugs: Cetuximab, Durvalumab
Study Phase: Phase 2/Phase 3
A Feasibility and Toxicity Analysis of Single Fraction Stereotactic Body Radiation Therapy for Post-Operative Non-Small Cell Lung Cancer
A Feasibility and Toxicity Analysis of Single Fraction Stereotactic Body Radiation Therapy for Post-Operative Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 10, 2025
Intervention Type: Other, Radiation
Study Phase: Phase 1
Three Pilot Studies of Stereotactic Body Radiation Therapy (SBRT) and Surgery in Non-small Cell Lung Cancer
Three Pilot Studies of Stereotactic Body Radiation Therapy (SBRT) and Surgery in Non-small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 08, 2025
Intervention Type: Other, Drug, Procedure
Study Drug: Stereotactic Body Radiation Therapy
Study Phase: Early Phase 1
A Pilot Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) in Central Non-Small Cell Lung Cancer
A Pilot Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) in Central Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 24, 2025
Intervention Type: Radiation
Study Phase: Not Applicable
A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Patients With Relapsed/Refractory Acute Myeloid Leukemia
A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Enrollment Status: Terminated
Publish Date: July 29, 2024
Intervention Type: Drug
Study Drug: Uproleselan
Study Phase: Phase 3
A Pilot Study of Photoacoustic Imaging (PAI) in H&Amp;N Cancer Patients
A Pilot Study of Photoacoustic Imaging (PAI) in H&Amp;N Cancer Patients
Enrollment Status: Terminated
Publish Date: April 10, 2023
Intervention Type: Procedure
Study Phase: Not Applicable
A Pilot Study of Photoacoustic Imaging (PAI)
A Pilot Study of Photoacoustic Imaging (PAI)
Enrollment Status: Terminated
Publish Date: March 31, 2023
Intervention Type: Procedure
Study Phase: Not Applicable
Body Warming to Alter [Thermo] Regulation and the Microenvironment [B-WARM] Therapy: A Pilot Study
Body Warming to Alter [Thermo] Regulation and the Microenvironment [B-WARM] Therapy: A Pilot Study
Enrollment Status: Completed
Publish Date: July 25, 2022
Intervention Type: Other, Procedure
Study Phase: Not Applicable
Two Versus Four Times-Weekly ALTENS for Treatment of Radiation-Induced Xerostomia: A Pilot Study
Two Versus Four Times-Weekly ALTENS for Treatment of Radiation-Induced Xerostomia: A Pilot Study
Enrollment Status: Completed
Publish Date: July 25, 2022
Intervention Type: Other, Procedure
Study Phase: Not Applicable
Analysis of Analgesia Regimens During Concurrent Chemoradiation for Head and Neck Cancer: A Pilot Study
Analysis of Analgesia Regimens During Concurrent Chemoradiation for Head and Neck Cancer: A Pilot Study
Enrollment Status: Completed
Publish Date: July 25, 2022
Intervention Type: Other, Drug
Study Phase: Phase 1
Survivor Warming to Alter Mood (S-WARM)
Survivor Warming to Alter Mood (S-WARM)
Enrollment Status: Withdrawn
Publish Date: May 12, 2022
Intervention Type: Other, Procedure
Study Phase: Early Phase 1
A Randomized, Open-Label Study to Assess the Pain, Toxicity, and Quality of Life Effects of Adding Venlafaxine to the Pain Management Regimen for Patients Treated With Chemoradiation for Head and Neck Cancer
A Randomized, Open-Label Study to Assess the Pain, Toxicity, and Quality of Life Effects of Adding Venlafaxine to the Pain Management Regimen for Patients Treated With Chemoradiation for Head and Neck Cancer
Enrollment Status: Completed
Publish Date: December 09, 2021
Intervention Type: Other, Drug
Study Drugs: Gabapentin, Methadone, Oxycodone, Venlafaxine, Venlafaxine Hydrochloride Extended-Release
Study Phase: Not Applicable
An Exploratory Trial to Estimate the Proportion of Patients With Tumor Cell Contaminated, Flow Positive Leukapheresis Products Collected With and Without Bortezomib as In-vivo Purging Prior to Autologous Stem Cell Harvest for Multiple Myeloma
An Exploratory Trial to Estimate the Proportion of Patients With Tumor Cell Contaminated, Flow Positive Leukapheresis Products Collected With and Without Bortezomib as In-vivo Purging Prior to Autologous Stem Cell Harvest for Multiple Myeloma
Enrollment Status: Completed
Publish Date: June 18, 2021
Intervention Type: Drug
Study Drugs: Bortezomib, Granulocyte Colony-Stimulating Factor (G-CSF), Mozobil
Study Phase: Phase 2
A Randomized, Open-Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide (19A+RICE) Chemotherapy vs. RICE in the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Who Are Candidates for Autologous Stem Cell Transplant
A Randomized, Open-Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide (19A+RICE) Chemotherapy vs. RICE in the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Who Are Candidates for Autologous Stem Cell Transplant
Enrollment Status: Terminated
Publish Date: May 17, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 16 Less Clinical Trials

785 Total Publications

ASPL couples the assembly of stress granules with their VCP-mediated disassembly.
ASPL couples the assembly of stress granules with their VCP-mediated disassembly.
Journal: Science advances
Published: October 08, 2025
Similar Doctors
Advanced in Transient Erythroblastopenia of Childhood
Dr. Mark H. Dewolfe
Hematology Oncology
Advanced in Transient Erythroblastopenia of Childhood
Dr. Mark H. Dewolfe
Hematology Oncology
5400 N Oak Trfy, Suite 101, 
Kansas City, MO 
 (9.4 miles away)
816-454-1658
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Mark Dewolfe is a Hematologist Oncology provider in Kansas City, Missouri. Dr. Dewolfe is rated as an Advanced provider by MediFind in the treatment of Transient Erythroblastopenia of Childhood. His top areas of expertise are Marginal Zone Lymphoma (MZL), Pleuropulmonary Blastoma, Non-Hodgkin Lymphoma, and Acute Mountain Sickness. Dr. Dewolfe is currently accepting new patients.

Experienced in Transient Erythroblastopenia of Childhood
Dr. Christopher F. Sirridge
Hematology Oncology | Oncology | Hematology
Experienced in Transient Erythroblastopenia of Childhood
Dr. Christopher F. Sirridge
Hematology Oncology | Oncology | Hematology

University Of Kansas Hospital Authority

12200 W 110th St, 
Overland Park, KS 
 (9.8 miles away)
913-574-2650
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Christopher Sirridge is a Hematologist Oncology specialist and an Oncologist in Overland Park, Kansas. Dr. Sirridge is rated as a Distinguished provider by MediFind in the treatment of Transient Erythroblastopenia of Childhood. His top areas of expertise are Hereditary Resistance to Anti-Vitamin K, Congenital Antithrombin 3 Deficiency, Protein C Deficiency, and Protein S Deficiency. Dr. Sirridge is currently accepting new patients.

Experienced in Transient Erythroblastopenia of Childhood
Dr. Rakesh Gaur
Hematology Oncology | Hematology | Oncology
Experienced in Transient Erythroblastopenia of Childhood
Dr. Rakesh Gaur
Hematology Oncology | Hematology | Oncology

Shawnee Mission Medical Center Inc

9301 W 74th St, 100 Ahmg Hematology Oncolo, 
Merriam, KS 
 (6.3 miles away)
913-632-9100
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Rakesh Gaur is a Hematologist Oncology specialist and a Hematologist in Merriam, Kansas. Dr. Gaur is rated as a Distinguished provider by MediFind in the treatment of Transient Erythroblastopenia of Childhood. His top areas of expertise are Colorectal Cancer, Lung Cancer, Myelodysplastic Syndrome (MDS), Pleuropulmonary Blastoma, and Bone Marrow Aspiration. Dr. Gaur is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Singh's expertise for a condition
ConditionClose
View All 13 Distinguished Conditions
View All 34 Advanced Conditions
View All 99 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile